Last reviewed 2026-05-28 · How we verify

ABP-671 plus allopurinol

Atom Therapeutics Co., Ltd · Phase 1 active Small molecule Quality 25/100

ABP-671 plus allopurinol is a Small molecule drug developed by Atom Therapeutics Co., Ltd. It is currently in Phase 1 development.

The mechanism combines ABP-671's undisclosed action with allopurinol's xanthine oxidase inhibition to reduce uric acid production.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ABP-671 plus allopurinol
Sponsor	Atom Therapeutics Co., Ltd
Modality	Small molecule
Phase	Phase 1

Mechanism of action

Allopurinol inhibits xanthine oxidase, the enzyme responsible for converting hypoxanthine to xanthine and xanthine to uric acid, thereby reducing uric acid levels. The specific mechanism and target of ABP-671 have not been publicly disclosed.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Drug-Drug Interaction Study of ABP-671 in Gout Patients (PHASE1)
Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout (PHASE2, PHASE3)
Extension Study of ABP-671 in Participants With Gout (PHASE2, PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ABP-671 plus allopurinol CI brief — competitive landscape report
ABP-671 plus allopurinol updates RSS · CI watch RSS
Atom Therapeutics Co., Ltd portfolio CI

Frequently asked questions about ABP-671 plus allopurinol

What is ABP-671 plus allopurinol?

ABP-671 plus allopurinol is a Small molecule drug developed by Atom Therapeutics Co., Ltd.

How does ABP-671 plus allopurinol work?

The mechanism combines ABP-671's undisclosed action with allopurinol's xanthine oxidase inhibition to reduce uric acid production.

Who makes ABP-671 plus allopurinol?

ABP-671 plus allopurinol is developed by Atom Therapeutics Co., Ltd (see full Atom Therapeutics Co., Ltd pipeline at /company/atom-therapeutics-co-ltd).

What development phase is ABP-671 plus allopurinol in?

ABP-671 plus allopurinol is in Phase 1.

Manufacturer: Atom Therapeutics Co., Ltd — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing